Halcyon Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 7.00 Cr
as on 29-12-2024
- Paid Up Capital ₹ 9.54 M
as on 29-12-2024
- Company Age 29 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.67 Cr
as on 29-12-2024
- Revenue -0.17%
(FY 2022)
- Profit 99.29%
(FY 2022)
- Ebitda 99.61%
(FY 2022)
- Net Worth -0.75%
(FY 2022)
- Total Assets -0.38%
(FY 2022)
About Halcyon Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.00 Cr and a paid-up capital of Rs 9.54 M.
The company currently has active open charges totaling ₹1.67 Cr.
Rajendra Lamba, Rashmi Lamba, and Parveen Kumari serve as directors at the Company.
- CIN/LLPIN
U24239HR1995PLC032570
- Company No.
032570
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
28 Feb 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- LocationHissar, Haryana
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Halcyon Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajendra Lamba  | Director | 02-Feb-2017 | Current |
| Rashmi Lamba | Director | 28-Feb-1995 | Current |
| Parveen Kumari | Director | 23-Apr-2019 | Current |
Financial Performance of Halcyon Pharmaceuticals.
Halcyon Pharmaceuticals Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 0.17% decrease. The company also saw a substantial improvement in profitability, with a 99.29% increase in profit. The company's net worth dipped by a decrease of 0.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Halcyon Pharmaceuticals?
In 2021, Halcyon Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Lamba Nursing Home Private LimitedActive 34 years 7 monthsRajendra Lamba and Rashmi Lamba are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Punjab National Bank Creation Date: 10 Mar 2004 | ₹0.50 M | Open |
Punjab National Bank Creation Date: 06 Jan 2003 | ₹2.50 M | Open |
Punjab Natrional Bank Creation Date: 01 Jan 1998 | ₹2.50 M | Open |
How Many Employees Work at Halcyon Pharmaceuticals?
Unlock and access historical data on people associated with Halcyon Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Halcyon Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Halcyon Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
